Posted on February 1, 2008 by jrowley
Cytori Therapeutics announced that they have enrolled their first two patients in an acute myocardial infarction clinical trial using adipose-derived cells prepared using their Celution™ device. The Celution™ device is an automated, tissue processing unit that isolates cells from adipose tissue derived via liposuction.
Filed under: Bioprocessing, Clinical Trials, Company Profiles, Cytori, Device-centric cell therapies, Regenerative Medicine, adult stem cell, autologous, cardiac regeneration, cell delivery, patient specific cell therapy, personalized medicine, stem cells | No Comments »
Posted on January 22, 2008 by jrowley
Pervasis Therapeutics announced that they have raised $9.75M to further develop their allogenic tissue engineered endothelial cell (EC) product for vascular health indications. Their Vascugel product is comprised of ECs grown in 3D collagen sponges that are implanted externally on blood vessels to prevent them from occluding. Pervasis has proven safety in a Phase I [...]
Filed under: Biomaterials, Bioprocessing, Clinical Trials, Company Profiles, Manufacturing, Pervasis, Regenerative Medicine, cell delivery, combination products, tissue engineered product, vascular regeneration | Tagged: end stage renal disease, endothelial cells, ESRD, gelfoam, tissue engineering, vascular health | No Comments »
Posted on December 31, 2007 by jrowley
The FDA has scheduled an April 10, 2008 meeting to “discuss scientific considerations for safety testing for cellular therapy products derived from human embryonic stem cells.” This meeting will be followed by another meeting on April 11 that will “discuss updates on 1) research management related to the September 29, 2005 review of research programs [...]
Filed under: Advanced Cell Technology, Clinical Trials, Embyonic Stem Cells, FDA, Geron, Novocell, Regenerative Medicine, cell delivery, regulatory, stem cells | 1 Comment »
Posted on December 23, 2007 by jrowley
Athersys and their cardiac parter, Angiotech, announced today that they got the ok from the FDA to begin a Phase I clinical study using Athersys’ Multistem adult stem cell product in acute myocardial infarction (MI). This is the second IND approval for Athersys in just over a month (and a welcome Christmas present for [...]
Filed under: Angiotech, Athersys, Biomaterials, Clinical Trials, Joint Ventures, Regenerative Medicine, cardiac regeneration, cell delivery | Tagged: Angiotech, Athersys, cardiac cell therapy, cell delivery, IND | No Comments »
Posted on November 26, 2007 by jrowley
CellCyte Genetics Corporation recently announced that US Patent No 7,282,222 was issued, a patent which they have exclusive rights to. The press release states that the patent covers unique methods and compositions “to deliver and direct stem cells to target organs in the body”, including cardiac tissue.
The focus of the patent addresses cell retention at [...]
Filed under: Clinical Trials, Intellectual Property, Regenerative Medicine, cardiac regeneration, cell delivery, stem cells | 1 Comment »
